

Impact Healthcare REIT

On track to meet dividend target

Impact Healthcare REIT's Q323 total return was 2.6%, or 8.5% over the first nine months of the year (9M23). With rent cover continuing to strengthen, rent collection back to 100% and 98% of drawn debt fixed or hedged, the company is well on track to meet its FY23 DPS target of 6.77p (+3.5%), fully covered by adjusted 'cash' earnings, with a yield of 8.6%.

| Year end | Net rental income (£m) | EPRA earnings* (£m) | EPRA EPS* (p) | EPRA NTA/ share (p) | DPS (p) | P/NAV (x)** | Yield (%)** |
|----------|------------------------|---------------------|------------------|------------------------|------------|----------------|----------------|
| 12/22 | 45.4 | 30.8 | 8.4 | 110.1 | 6.54 | 0.72 | 8.3 |
| 12/23e | 53.4 | 33.9 | 8.2 | 114.5 | 6.77 | 0.69 | 8.6 |
| 12/24e | 56.2 | 34.6 | 8.3 | 118.9 | 6.96 | 0.66 | 8.8 |
| 12/25e | 59.4 | 38.4 | 9.3 | 123.9 | 7.10 | 0.64 | 9.0 |

Note: *EPRA earnings exclude fair value movements on properties and interest rate derivatives. **P/NAV and yield are based on the current share price.

100% of rents due collected in Q3

The Q323 total return comprised a 1.1% increase in EPRA NTA per share to 114.38p and a quarterly dividend of 1.6925p. The main driver of NTA growth was a 1.3% like-for-like increase in property valuation and some slight yield tightening in certain assets with consistently strong rent cover. Completed rent reviews were at an average uplift of 4.69% per year and added £0.3m to contracted rent (£48.4m). 100% of Q3 rents due were received, as was consistently the case until the beginning of the year, when one of Impact's 13 care home tenants (Silverline) ceased payment. The seven homes that were previously leased to Silverline are now in a process of turnaround under the new operator, during which time no rent is due. Having dipped to 98% in H1, collection year to date is now 99%, with no indications of any wider tenant stress. Our EPRA NTA per share forecasts are each increased by c 2% for FY23–FY25, with no other changes to forecasts.

Continued strengthening of rent cover

Strong fee growth, improved occupancy and easing staff shortages continue to offset inflationary cost pressures on tenants. Underlying rent cover had already reached pre-pandemic levels, at 1.8x in H1 (on a rolling 12-month basis). Currently available tenant reporting data, covering 80% of the portfolio, indicate that it increased further in Q3. Annual underlying fee growth for Impact's tenants was 15% in June, and resident occupancy had increased to 88.2% from 86.6% in December (and a pandemic low of 79%). Occupancy was stable during Q3 and in this respect we note indications across the sector that some operators are increasingly focused on ensuring that fees for new residents are appropriate to the level of required care, as opposed to simply prioritising occupancy. Nevertheless, further progress towards the pre-COVID-19 'norm' of a low 90% level would only reinforce rent cover.

Valuation: Income-driven, long-term returns

The FY23 DPS target represents an attractive yield of 8.6% and we forecast continued growth in adjusted 'cash' earnings. Meanwhile, the shares trade at a c 30% discount to EPRA NTA per share.

Trading update

Real estate

26 October 2023

| Price | 79 p |
|---------------------------------|-------------|
| Market cap | £327m |
| Gross debt at 30 September 2023 | £178.8m |
| Gross LTV at 30 September 2023 | 27.0% |
| Shares in issue | 414.4m |
| Free float | 90% |
| Code | IHR |
| Primary exchange | LSE |
| Secondary exchange | N/A |

Share price performance



Business description

Impact Healthcare REIT, traded on the Main Market of the London Stock Exchange, invests in a diversified portfolio of UK healthcare assets, primarily residential and nursing care homes, let on long leases to high-quality operators. It aims to provide shareholders with attractive and sustainable returns, primarily in the form of dividends, underpinned by structural growth in demand for care.

Next event Q323 DPS paid 24 November 2023

Analyst

Martyn King +44 (0)20 3077 5700

financials@edisongroup.com

Edison profile page

Impact Healthcare REIT is a research client of Edison Investment Research Limited



Additional details

Q323 marked the third consecutive quarter of investment property valuation growth following the significant weakness experienced in Q422, broadly across the property sector. Care home properties have continued to prove more resilient than the wider sector, supported by strong sector fundamentals, long leases (Impact's weighted average unexpired lease term is 21 years) and indexed income growth. Rental income is again driving valuation uplifts, with some additional benefit from slight yield tightening. The Q3 EPRA 'topped-up' net initial yield was 6.91% versus 6.95% in June (December 2022: 6.98%).

| Pence per share | EPRA NTA | IFRS NAV |
|--|----------|----------|
| Opening value | 113.08 | 113.64 |
| Revaluation gains on investment properties | 1.30 | 1.30 |
| Purchase of interest rate caps | (0.42) | |
| Revaluation loss on interest rate cap | | (0.28) |
| Net remaining contribution to reserves | 2.11 | 2.11 |
| Q223 dividend paid | (1.69) | (1.69) |
| Closing value | 114.38 | 115.08 |
| Percentage quarterly change | 1.1% | 1.3% |

The positive valuation performance has driven positive total accounting returns in each quarter year to date.

| Exhibit 2: Quarterly EPRA NTA total r | | | | |
|---------------------------------------|-------|-------|-------|-------|
| Pence per share | Q123 | Q223 | Q323 | 9M23 |
| Opening NAV | 110.1 | 112.2 | 113.1 | 110.1 |
| Closing NAV | 112.2 | 113.1 | 114.4 | 114.4 |
| Dividends paid | 1.6 | 1.7 | 1.7 | 5.0 |
| Annualised NAV total return | 3.4% | 2.3% | 2.6% | 8.5% |
| Of which dividends paid | 1.5% | 1.5% | 1.5% | 4.6% |
| Of which change in NAV | 2.0% | 0.7% | 1.1% | 3.9% |

The year-to-date return continues a strong track record of positive NAV/accounting total returns since listing in March 2017, with an average of 7.1% pa. Even in 2022, IHR's robust cash flows enabled the company to report a dividend-driven total return of 3.7%. Since listing, progressive dividends have generated 70% of returns.

| Exhibit 3: Strong long-term track record of EPRA NTA total returns | | | | | | | | |
|--|-------|-------|-------|-------|-------|-------|--------|-----------|
| Pence per share | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 9M23 | FY17-9M23 |
| Opening NAV | 97.9 | 100.6 | 102.9 | 106.8 | 109.6 | 112.4 | 110.08 | 97.9 |
| Closing NAV | 100.6 | 102.9 | 106.8 | 109.6 | 112.4 | 110.1 | 114.5 | 114.5 |
| Dividends paid | 3.0 | 6.0 | 6.1 | 6.3 | 6.4 | 6.5 | 5.0 | 39.3 |
| Annualised NAV total return | 7.2% | 8.2% | 9.7% | 8.5% | 8.4% | 3.7% | 8.6% | 57.1% |
| Of which dividends paid | 3.1% | 6.0% | 6.0% | 5.9% | 5.8% | 5.8% | 4.6% | 40.1% |
| Of which change in NAV | 2.8% | 2.3% | 3.7% | 2.6% | 2.6% | -2.1% | 4.0% | 17.0% |
| Average annualised return | | | | | | | | 7.1% |


Source: Impact Healthcare REIT data, Edison Investment Research

Dividends have been fully covered by EPRA earnings in each year since listing and, as cash rents have continued to increase, have been well covered on an adjusted 'cash' basis. We expect Impact to continue to target progressive dividends and, despite the increased cost of borrowing, we forecast a fully covered dividend in both this year and next, albeit with cash cover slightly lower than in previous years.



With an additional £50m of hedging acquired during Q3¹, the interest costs on 98% of drawn debt (£179m) are now fixed or hedged, removing the primary risk to our earnings forecasts. The current average cost of drawn debt, including hedging and fixed-rate borrowings, is 4.47% and although the hedging is of relatively short duration (£50m matures at end-2024 and £50m in August 2025), we note that:

- this provides Impact with the flexibility to review its longer-term financing at a point when a decline in interest rates is implied by the current market yield curve; and
- the completion of development and asset management projects, a restoration of rents from the properties in turnaround, as well as continuing indexed rental growth that we forecast will provide an additional offsetting uplift in revenues.



Source: Impact Healthcare REIT data, Edison Investment Research

A further £50m interest rate cap at a cost of £1.76m, which caps SONIA at 4.0% for two years.



| ear to 31 December (£m) | 2020 | 2021 | 2022 | 2023e | 2024e | 202 |
|--|---------------|----------------|---------------|------------|---------------|----------|
| Cash rental income* | 25.9 | 30.5 | 39.1 | 46.3 | 47.6 | 5 |
| RS adjustments for guaranteed uplifts and lease incentives | 4.9 | 5.9 | 6.4 | 7.4 | 8.6 | |
| ross rental income | 30.8 | 36.5 | 45.4 | 53.7 | 56.2 | 5 |
| et other income/(expense) | (0.0) | 0.0 | 0.0 | 0.0 | 0.0 | |
| ad debt charge | 20.0 | 20.5 | 45.4 | (0.4) | 50.0 | |
| let rental income dministrative & other expenses | 30.8 (5.3) | 36.5 (5.8) | 45.4 (7.0) | (7.6) | 56.2 (7.7) | 5 (1 |
| Realised gain on disposal | 0.2 | 0.3 | 0.1 | (0.0) | 0.0 | (|
| Operating profit before change in fair value of investment properties | 25.7 | 31.0 | 38.6 | 45.7 | 48.5 | 5 |
| Inrealised change in fair value of investment properties | 5.6 | 4.2 | (16.3) | 12.9 | 10.0 | 1 |
| Operating profit | 31.3 | 35.2 | 22.3 | 58.6 | 58.5 | (|
| let finance cost | (2.5) | (3.3) | (5.4) | (10.8) | (13.9) | (1 |
| rofit before taxation | 28.8 | 32.0 | 16.9 | 47.9 | 44.5 | |
| ах | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| rofit for the year (IFRS) | 28.8 | 32.0 | 16.9 | 47.9 | 44.5 | 4 |
| djust for: | | | | | | |
| ealised and unrealised gain/(loss) on investment properties | (5.7) | (4.5) | 14.3 | (12.9) | (10.0) | (1 |
| hange in fair value of interest rate derivatives | 0.1 | (0.1) | (0.4) | (1.1) | 0.0 | |
| PRA earnings | 23.1 | 27.4 | 30.8 | 33.9 | 34.6 | |
| ental income arising from recognising rental premiums & fixed rent uplifts | (4.9) | (6.0) | (6.5) | (7.5) | (8.6) | |
| mortisation of loan arrangement fees | 0.7 | 1.0 | 1.2 | 1.5 | 1.5 | |
| terest received on rate cap | 0.0 | 0.0 | 0.1 2.1 | 1.5 0.1 | 2.5 0.0 | |
| ther adjustments djusted earnings | 19.1 | 22.7 | 27.7 | 29.5 | 29.9 | |
| verage number of shares in issue (m) | 319.0 | 339.8 | 390.1 | 414.2 | 414.4 | 4 |
| asic & diluted IFRS EPS (p) | 9.02 | 9.41 | 4.33 | 11.56 | 10.75 | 1 |
| PRA EPS (p) | 7.25 | 8.05 | 8.37 | 8.19 | 8.34 | <u>'</u> |
| djusted EPS (p) | 5.98 | 6.68 | 7.11 | 7.11 | 7.22 | |
| vidend per share (declared) | 6.29 | 6.41 | 6.54 | 6.77 | 6.96 | |
| PRA earnings dividend cover | 115% | 126% | 128% | 121% | 120% | 1 |
| djusted earnings dividend cover | 95% | 104% | 109% | 105% | 104% | 1 |
| AV total return | 8.5% | 8.4% | 3.8% | 10.7% | 9.3% | (|
| PRA cost ratio | 17.1% | 15.8% | 16.6% | 15.2% | 13.7% | 13 |
| ALANCE SHEET | | | | | | |
| vestment properties | 405.7 | 437.6 | 504.3 | 616.7 | 640.6 | 6 |
| ther non-current assets | 15.9 | 62.0 | 68.1 | 38.0 | 46.6 | |
| on-current assets | 421.6 | 499.7 | 572.4 | 654.6 | 687.2 | 7 |
| ash and equivalents | 8.0 | 13.3 | 22.5 | 17.1 | 15.6 | |
| ther current assets | 0.1 | 1.6 | 1.5 | 5.3 | 2.2 | |
| urrent assets | 8.1 | 14.8 | 24.1 | 22.4 | 17.8 | (40 |
| orrowings | (74.2) | (110.9) | (122.4) | (186.1) | (197.6) | (19 |
| ther non-current liabilities | (2.8) | (2.6) | (4.3) | (2.4) | (2.4) | (2) |
| on-current liabilities | (77.0) 0.0 | (113.5) 0.0 | (126.7) | (188.5) | (200.0) | (20 |
| orrowings ther current liabilities | (3.1) | (6.7) | (9.1) | (10.8) | (11.4) | (1 |
| urrent Liabilities | (3.1) | (6.7) | (23.9) | (10.8) | (11.4) | (1 |
| et assets | 349.5 | 394.2 | 445.9 | 477.7 | 493.6 | 5 |
| djust for derivative financial liability/(asset) | (0.0) | (0.1) | (0.4) | (3.2) | (0.8) | |
| PRA net tangible assets (NTA) | 349.5 | 394.2 | 445.6 | 474.5 | 492.9 | 5 |
| eriod end shares (m) | 319.0 | 350.6 | 404.8 | 414.4 | 414.4 | 4 |
| RS NAV per ordinary share | 109.6 | 112.4 | 110.2 | 115.3 | 119.1 | 1 |
| PRA net tangible assets (NTA) per share | 109.6 | 112.4 | 110.1 | 114.5 | 118.9 | 1 |
| ASH FLOW | | | | | | |
| et cash flow from operating activities | 21.0 | (13.9) | 29.5 | 38.2 | 41.1 | |
| urchase of investment properties (including acquisition costs) | (88.5) | (28.1) | (71.9) | (48.6) | (6.0) | |
| apital improvements | (1.7) | (1.1) | (11.2) | (4.5) | (8.0) | |
| her cash flow from investing activities | 0.9 | 1.6 | 5.4 | 2.2 | 0.0 | |
| et cash flow from investing activities | (89.3) | (27.6) | (77.7) | (50.8) | (14.0) | |
| sue of ordinary share capital (net of expenses) | 0.0 | 34.6 | 60.5 | (0.0) | 0.0 | |
| epayment)/drawdown of loans | 51.2 | 38.2 | 27.7 | 48.5 | 10.0 | |
| vidends paid | (20.0) | (21.9) | (25.7) | (27.8) | (28.6) | (2 |
| her cash flow from financing activities | (2.8) | (4.1) | (5.1) | (13.5) | (10.0) | (|
| et cash flow from financing activities | 28.5 | 46.8 | 57.4 | 7.2 | (28.6) | (4 |
| et change in cash and equivalents | (39.8) | 5.3 | 9.3 | (5.5) | (1.5) | |
| pening cash and equivalents | 47.8 | 8.0 | 13.3 | 22.5 | 17.1 | |
| losing cash and equivalents | 8.0 | 13.3 | 22.5 | 17.1 | 15.6 | /40 |
| alance sheet debt | (74.2) | (110.9) | (137.2) | (186.1) | (197.6) | (19 |
| namortised loan arrangement costs | (2.2) | (3.6) | (5.1) | (4.7) | (3.2) | /10 |
| et cash/(debt) | (68.4) | (101.3) | (119.7) | (173.7) | (185.2) | (19 |
| ross LTV (net debt as % gross assets) | 17.8% | 22.3% | 23.8% | 28.2% | 28.5% | 2 |



General disclaimer and copyright

This report has been commissioned by Impact Healthcare REIT and prepared and issued by Edison, in consideration of a fee payable by Impact Healthcare REIT. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2023 Edison Investment Research Limited (Edison)

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.